Luigi D. P.
- Country
- Sweden
- Department
- Studie behandlingsavdelning, B08:09
Research Overview
- Biomarker-Driven Targeted Therapy in Advanced Cancer: A Swedish Nationwide Clinical Trial (FOCU.SE)
- Evaluation of PF-08046031 in Adults With Advanced Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and Esophageal Cancer
- Evaluation of PF-08046050 (SGN-CEACAM5C) in Adults with Advanced Non-Small Cell Lung Cancer, Colorectal Cancer, and Other Solid Tumors
Data & Insights
Has run more than one trial at 117 of 313 partner sites.
Specializations
Lung Cancer Specialization
This investigator demonstrates extensive focus on both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) treatments, with particular emphasis on advanced and metastatic disease states.
- Early-stage NSCLC management
- Extensive-stage SCLC therapy
- Advanced metastatic lung cancer
Integrates various therapeutic approaches including radiotherapy and immunotherapy for lung cancer treatment.
Innovative Treatment Approaches
The investigator specializes in combining immunotherapy with other treatment modalities, particularly focusing on novel therapeutic combinations.
- Combined modality treatments
- Stereotactic body radiotherapy
- Targeted therapeutic agents
Explores advanced therapeutic strategies for thoracic oncology patients.
Additional Oncology Interests
Beyond lung cancer, the investigator's expertise extends to various solid tumors including gastrointestinal malignancies.
- Colorectal cancer
- Gastric and gastroesophageal cancers
- Pancreatic carcinoma
Investigates novel therapeutic approaches for advanced solid tumors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.